Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (16308)	10/3/2003 4:07:52 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

O.K. I was wrong. I thought the sale of the royalty for Retuxan was a good move. Your 20/20 hindsight is much better than mine. I admit that you never liked the idea. So just get to the issues, rather than explaining that your vision was not hindsight. How, are we supposed to know that this present trial is not paid for by Xoma? How do you know, that the researcher is paying for the trial? Not saying you are not correct, just want to learn how to see the same thing in the future. Now you seem to indicate that orphan drug designation could be obtained, if the "non proven and non sense" probe produces good results. Please just a straight answer, no games. We can go back to word games later. tia She is your aunt, not mine.